Background: Acute urinary retention, is one of the main complications of Benign Prostatic Hyperplasia (BPH) in elderly patients. Trial Without Catheter (TWOC) is a way to evaluate whether a patient can urinate spontaneously after an episode of urinary retention. For each group, drugs were given orally once daily for seven days. Efficacy of TWOC was assessed by the ability of spontaneous urinary after the first 24 hour post urethral catheter treatment, with Q-max result on uroflowmetry ≥ 5 cc/sec and PVR ≤ 100 cc. Result: All subjects from K1 and K4 experience a recurrent episode of urinary retention (100%), 83.3% in K3 and 66.7% in K6. In the combination group, K2 had 50% incidence of repeat urinary retention, while K5 had16.7%. From the whole group, a statistically significant difference with p <0.05 only can be found in K1 and K5 (p = 0.02).
INTRODUCTION
Prevalence of benign prostatic hyperplasia (BPH) is 253 in each 1000 population. In the 60-69 year age group, the prevalence increases to 430 in each 1000 male population.
1 Above 50 years, the incidence of BPH increased by 10% for each decade and reached 80% in men in the 80's. 2 Histologic, and clinical criteria for BPH were used as a basis for calculating prevalence and incidence. 3 In Indonesia, no accurate data describes the prevalence or incidence of BPH. From 1994 until 2013, about 3.804 cases of BPH were found at Cipto Mangunkusumo Hospital (RSCM) with an average age are 66.61 years old. 4 Stromal cell and the prostate epithelium hyperplasia in the periurethral area, commonly occur and can be seen in the fetal developmental process. This process is the basis for the embryonic concept reawakening in BPH. However, biomolecular aetiology underlying BPH is still unclear. Androgens, estrogens, stromal-epithelial interactions, growth factors and neurotransmitters, either independently or dependently can play a role as the aetiology of prostate hyperplasia. Further research has shown that the increased size of prostate is due to an increase in stromal and epithelial cells proliferation and also the disruption of apoptotic prostate cells. 3 Prostate inflammation implies the aetiology and pathogenesis of BPH through static factor (prostate enlargement) and dynamic factor (smooth muscle contraction). Chronic inflammation is strongly associated with the degree of severity and accelerated deterioration of lower urinary tract syndrome (LUTS). Destruction of stromal and glandular prostate elements by proinflammatory cells causes tissue damage and ultimately results in prostate volume enlargement. Compared with non-inflammatory prostate tissue, BPH patients accompanied by prostate inflammation exhibit greater prostate volume, more severe LUTS symptoms and a higher tendency for urinary retention. 5, 6 Acute urinary retention (AUR) defined as a sudden inability to involuntary urination. About 10% AUR is'80s, and 33% AUR is '89s.
7
In male, AUR can be caused by BPH. In the United States and the United Kingdom, transurethral resection of the prostate (TURP) procedure is applied in 20-42% of BPH patients with AUR complications. 8 The incidence of AUR in men is 0.4-25% each year. 9 Other study said that 44% of patients with BPH have an acute urinary retention. 10 Acute urinary retention can be caused by a sudden stimulation of α-adrenergic receptor. This possibly as a result of an infarction in prostate tissue. This condition will increase smooth muscle tonus in prostate and capsule, so the bladder outlet resistance rises. The dominance of sympathetic nervous activity will also increase smooth muscle tonus at the bladder neck and posterior urethra. 10 Trial without catheter (TWOC) is a way to evaluate whether patients can urinate spontaneously after urinary retention. After the catheter is released, the patient is required to perform urine flow (uroflowmetry) by inspection and the measurement of residual urine (residual microscopic volume). Trial without catheter can only be conducted after administration of α1-blockers (for a minimum of 3-7 days), in patients with the first episode of acute urinary retention and has not yet established a definitive diagnosis. 3, 10 Tamsulosin, is an α1a adrenergic receptor antagonist. It is used to treat symptomatic BPH, chronic prostatitis, help the passage of kidney stones and for urinary retention. Tamsulosin and other medications in alpha blockers class works by relaxing bladder neck and muscle fibres in prostate and making it easier to urinate. [11] [12] [13] Thus, increasing the success of TWOC. 8, 13, 14 Acute urinary retention can also cause by inflammation process. Mild to severe inflammation can be found in 55% of BPH patients with AUR. 15 Cyclooxygenase (COX) is a major enzyme in the conversion of arachidonic acid into prostaglandins on the inflammatory process. One of the COX enzyme isoforms is COX-2. Cyclooxygenase will induce prostaglandins and increased expression of Bcl-2. Prostaglandins will lead to an increased growth of prostate smooth muscle cells, and Bcl-2 will inhibit cells apoptosis in prostate tissue. As a result, the prostate will enlarge.
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Administration of COX-2 inhibitors can reduce and even stop the inflammatory processes occurring in BPH. Several COX-2 inhibitors such as celecoxib, tenoxicam and meloxicam have been used as the treatment of BPH. Oral celecoxib 10 milligrams (mg) once daily for one month are sufficient for the refractory nocturia complaints. 17 Combination of tenoxicam 20 mg and alpha-blocker increase international prostate symptom score (IPSS), IPSS-quality of life (IPSS-QoL) and overactive bladder symptom score (OABSS) in LUTS patients caused by BPH compared to control group (receiving alphablockers only). 18 Combination of oral meloxicam 15 mg and doxazosin 4 mg once daily for six weeks increase the maximum urine flow rate (Qmax) and decrease prostate blood flow in BPH patients with LUTS. 19 A systematic review and meta-analysis of non steroid anti-inflammation drugs (NSAID) effect by Kahokehr et al. (2013) concluded that there were improvements in LUTS and urinary emissions as a result of NSAID administration. No serious adverse effects on NSAID administration is shown. 20 The TWOC procedure as management of AUR in BPH patients is applied to more than 79% cases in France, Asia, Latin America, Algeria, and middle east countries. Success rate of TWOC after alpha-blocker treatment in all age groups of BPH with AUR reached 63.4%. 10 Success rate of TWOC after tamsulosin 0.4 mg compared with placebo was 63% and 37%, respectively. Although the success of TWOC as the primary end-point between the tamsulosin group and the placebo group was not statistically significant, re-catheterisation in tamsulosin group proved to be lower and statistically significant compared with the placebo group. 11, 12 Until now, rarely or even no studies have used meloxicam or other COX-2 preparations for TWOC procedures. Therefore, a research should be performed to proves whether meloxicam alone or combination (meloxicam and tamsulosin) is more effective than tamsulosin alone in TWOC BPH patients who experienced the first episode of urinary retention.
METHODS
The study was designed in randomised posttest-controlled group.Subjects were randomized to 6 treatment groups. There are three doses of drugs (D) for this research. After the treatment, urethral catheter was removed. Recurrent urine retention within 24 hours after the release of the catheter was clinically assessed. In case of retention, a recatheterisations classified as a failed group. The successful group defined as a spontaneous micturition sample, IPSS scoreless than or equal to 7, maximum urinary emission (Q-max) were more than 5 cc/ sec on uroflowmetric examination (2nd and 3rd weeks posttreatment), with residual urine (PVR) less than 100 cc measured by transabdominal sonography. Three weeks medication for each post-treatment group was given and observed for the side effects of drugs.
Subject
The study population was the patient who experienced first urine retention due to prostate enlargement at regional general hospital Dr Soetomo and RS Airlangga University Surabaya.
The inclusion criteria of this study are: 
DATA ANALYSIS
The relationships between variables were analysed by One-way ANOVA, Mann-Whitney test, Kruskal-Wallis test, Tamhanne and Fisher test with 95% confidence level using SPSS software support. Urine emission (Q-max) in post TWOC patients Based on statistical data analysis, data were not normally distributed, and the variant data were not homogenous (p <0.05). Therefore, a Kruskal-Wallis test were performed. Based on the data analysis there was a significant difference between groups in Q-max parameter (Table 2) . Based on the results, there is a significant difference in each group. A MannWhitney test (Post hoc test) were performed to determine the differences between groups. Based on the MannWhitney test there were statistically significant difference of statistical Q value between K5-K4 and K1-K5 (Table 3) .
RESULTS

Patient Characteristics
Post voiding residual (PVR) in post TWOC patients
Data were normally distributed (p > 0.05). Therefore, one-way ANOVAtest was used. There were a significantly differences of in each group (Table 4) .
Based on thehomogeneity test of variance, data variant was not homogeneous. Therefore, Tamhanne Post hoc test was performed. Based on it, a significant difference in PVR parameter can be found in K1 compared with K5 group. Similarly, K4 group compared with K5 showed p-value < 0.05 (Table 5) .
Voiding volume (VVol) in patient post
TWOC.
Data were not normally distributed and the variant data were not homogenous (p <0.05). Therefore, data were analysed by Kruskal-Wallis test. Based on this test, no significant difference of VVol value in each group (Table 6) . 
Comparison of effectiveness between treatments to trial without catheter (TWOC) Success in patients with urinary retention
Based on Fisher test, no significant difference of TWOC success rate between K1-K2,K3-K4 and K5-K6 in 16 Fr catheter therapy group for TWOC ( Table 7) .
The statistically significant differences are only found on K1 compared with K2 with p value < 0.05. (Table 8 ).
This study compared the differences between groups above. Based on the Fisher test, a statistically significant difference can be found in group K1 and group K5 (p value < 0.05). The use of catheter 20 Fr + combination meloxicam 15 mg and tamsulosin 0,4 mg (K5) had a better effect compared with catheter group 16 Fr + meloxicam 15 mg (K1) ( Table 9 ). Table 10 
Side effects of drugs treatment
DISCUSSION
Acute urinary retention is an important issue that often occurs in elderly and causes morbidity. Acute urinary retention is one of BPH complication. One in 10 men in the seventh decade suffering from acute urinary retention. This risk will be increased three times in the eighth decade. The first action performed on an incident of acute urinary retention is by performing the catheterisation. This action can reduce decompression of the bladder and subsequent operative action. However, immediate operative action has a higher rate of complications of morbidity and mortality compared to elective surgery. 10 Alpha blockers treatment cause a greater TWOC success rate in acute urinary retention patients with BPH without surgery after catheter release. The use of alfuzosin 10 mg once daily may have greater TWOC success rate (61.9%) than with a placebo of only (47.9%) for six months of therapy. Alpha-1-blockers effective for LUTS management and acute urinary retention with a decreased sympathetic tone, reduced bladder outlet resistance and PVR. Prostate inflammation causes the destruction of stromal and glandular prostate elements by pro-inflammatory cells. The process leads to an increase in PSA and prostate volume levels.
Increased prostate volume affects the static factor. Static factors (prostate enlargement), dynamic factor (smooth muscle contraction) and prostate inflammation will cause LUTS symptoms. In the decompensation phase, LUTS patients fall on acute urinary retention. Treatment of NSAIDs in LUTS is now considered to manage BPH. As it is known that in the prostate there was a large amount of COX-2 expression present in prostate smooth muscle cells. The use of a finasteride and rofecoxib combination had better results in reducing LUTS symptoms in BPH patients compared with single-treatment finasteride. 10, 22 Alpha-blocker reduces bladder outlet resistance through smooth muscle relaxation of prostate tissue. This drug will facilitate the process of spontaneous micturition. Giving meloxicam 15 mg as an anti-inflammatory reduces the inflammatory process of prostate tissue. Decrease of prostate tissue oedema and healing phase will be achieved. In the end, the prostate volume is reduced. This condition will decrease static factors of BPH pathogenesis and facilitate spontaneous voiding in urinary retention patients. 4, 10 This study found that the combination of meloxicam 15 mg and tamsulosin 0.4 mg was superior to meloxicam and tamsulosin 0.4 mg alone. In this study, prostate and IPP volumes were not confounding variables against TWOC outcomes. This result is not similar with some reviews that reporting IPP and prostate volume are important factors influence the success of TWOC. 3, 4, 10 Characteristics and size of the different samples are an acceptable reason for this differences. Duration of alpha-blocker administration and analysis of other comorbid factors that were not included in this study may also contribute to this differences. The highest success rate of TWOC was shown in the group treated with the combination of meloxicam 15 mg and tamsulosin 0. 4 23 Combination of meloxicam 15 mg and tamsulosin can improve natural micturition ability, Qmax, and decrease PVR. This results also reported by another study, which found that the use of a combination of meloxicam and tamsulosin was better than single-tamsulosin therapy in LUTS symptoms in BPH. 24 Combination therapy of meloxicam 15 mg and doxazosin 4 mg per oral once daily for six weeks was better in increasing Qmax and decreasing prostate blood flow in BPH patients with LUTS. 19 In a systematic review and meta-analysis of NSAIDs effects in LUTS BPH patient it was concluded that there were improvements in LUTS and urinary emissions as a result of NSAID administration. No serious adverse effects found. 20 One clinical trial reported that the success rate of TWOC after tamsulosin 0.4 mg compared to placebo about 63% and 37% respectively, and 33.8% and 24.3% respectively. 11 Other study concluded that COX-2 inhibitors combined with alpha-blockers could improve the effectiveness of therapy for secondary LUTS due to BPH without significant effects. Thehigh success of TWOC in this study may be due to the synergistic effect between meloxicam and tamsulosin. The ability of meloxicam inhibiting COX-2 is thought to play an important role. Several studies have shown that high expression of COX-2 and prostaglandin may cause partial obstruction of the bladder outlet.25-27 The role of tamsulosin in reducing sympathetic tone in bladder outlets and prostate stroma also contributes to the success of TWOC. A study reported that tamsulosin was better than placebo with odds ratio 2.34.
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This study also showed that a single treatment of 15 mg meloxicam, has the lowest success rate compared to other groups. Therefore, in this study, it appears that acute urinary retention for the first episode of BPH patients is more likely to be dominated by sympathetic tone activity compared with inflammation.
The sssue of acute inflammation or chronic inflammation of the prostate as a presumed cause of acute urinary retention in BPH has been investigated. The study reported that the incidence of acute urinary retention was three times more common in chronic inflammatory prostate. 15 Chronic inflammation of the prostate also tends to shorten the period of BPH patients with LUTS falling under acute urinary retention conditions. 5 Therefore, further investigation is necessary to prove the dominance of sympathetic factors compared with inflammation in patients with BPH who have acute urinary retention of the first episode. The failure of meloxicam enhancing the success of TWOC is also affected by the paradoxical effect that NSAIDs themselves are risk factors for urinary retention. AUR risk 2.02 times higher in NSAID users than people who do not use it as therapy. Inhibitory effect of COX-2 enzyme in the bladder caused the decrease of prostaglandin synthesis and impaired of bladder contractions especially in AUR. 28 This study shows that although the combination of meloxicam 15 mg and tamsulosin 0.4 mg has the best effect in reducing acute urinary retention, it is important to note that use of both treatment still has side effects. Side effects caused by the combination of these drugs more significant than other groups. Side effects of combination therapy such as dyspepsia and dizziness (66.6%), dizziness (16.6%) and dyspepsia (8.3%) are still higher compare with tamsulosin alone (dizziness in 33.3%) and also meloxicam alone(dyspepsia 41.6%). In this study, it seems that numerous side effects were caused by the mechanism of each drug. Meloxicam is tolerable and relatively safe for atrisk groups such as geriatrics, renal insufficiency patients, and paediatrics. No cardiovascular severe or gastrointestinal problems can be found in treatment with meloxicam for 3 to 12 weeks. [29] [30] [31] Compared with diclofenac, piroxicam, ibuprofen and indomethacin groups; meloxicam has a lower incidence rate in gastrointestinal reactions, dyspepsia, gastritis, abdominal pain, and gastrointestinal bleeding. 31 However, an adequate explanation for the side effects possibility should be given to the patient. Combination therapy should be noticed in patients who receive antihypertensive treatment and have a history of dyspepsia. Further research is needed to prove the dominance between the role of sympathetic factors compared with inflammatory factors, including specifically the dominance of the role of chronic inflammation of prostate tissue compared with acute inflammation, in patients with BPH who have acute urinary retention of the first episode.
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